David Frenay, CEO Emolytics :
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES II led its first investment round. It was a pleasure to work with such a professional and helpful team during this entrepreneurial adventure. VIVES II definitely made Emolytics a better company through their strategic help and guidance. They brought their professionalism and experience on the table, along with operational help to fulfill their "service to the society" mission, at lot farther than any traditional financial investor would have done. I would be happy and honored to work with them again in the future."
